Amphista Therapeutics, a pioneering company in the development of next-generation targeted protein degradation (TPD) therapies, has announced the appointment of three senior leaders to bolster its clinical development efforts. The new roles include Dr. Lisa Butler as Senior Vice President of Clinical Operations, Dr. Alexandra Sevko as Vice President of Translational Science, and Nicola Lindsay as Head of Project and Portfolio Management. This strategic enhancement comes as the company prepares to advance its lead candidate, AMX-883, into clinical trials next year.
Martin Pass, Chief Development Officer at Amphista, expressed enthusiasm about the new appointments, stating, “As we prepare to enter the clinic next year with our lead asset, AMX-883, we are delighted to announce the appointment of these three exceptional leaders. The high-caliber expertise that we have assembled will be instrumental to the successful execution of our clinical programs and in establishing a strong foundation to support future growth and deliver on our mission to bring transformative TPD medicines to patients.”
The newly appointed leaders bring extensive experience to Amphista. Dr. Lisa Butler has over 25 years of clinical research leadership, having worked with various biotech and pharmaceutical firms, including AstraZeneca. Her robust background in clinical program delivery and quality oversight will be pivotal in ensuring that Amphista”s studies are executed efficiently and to high standards.
Dr. Alexandra Sevko, with more than 20 years of experience in immuno-oncology and translational research, has held positions at esteemed institutions such as Imperial College London and University College London. She will oversee the translational program at Amphista, focusing on clinical biomarker development to facilitate informed decision-making and translate research into tangible patient outcomes.
Nicola Lindsay joins Amphista with over 25 years in the industry, previously working at NodThera and major pharmaceutical companies including GSK and Pfizer. As a PMP-certified project manager, she has a proven track record of leading projects from lead optimization through clinical proof of concept across various therapeutic areas.
In October 2025, Amphista announced its first clinical development candidate, AMX-883, a BRD9 degrader for acute myeloid leukemia (AML). This announcement was significant, following earlier disclosures outlining novel mechanisms of action for TEAD degradation via FBX022 and for SMARCA2 degradation through induction of E3 ligase DCAF16.
About Amphista Therapeutics: The company is committed to transforming the treatment landscape for patients with severe diseases, including cancer and neurodegenerative disorders, by developing advanced TPD medicines. Utilizing its proprietary Eclipsys platform, Amphista creates unique bifunctional Targeted Glue therapeutics with innovative mechanisms and superior drug-like properties. The portfolio aims to offer first- and/or best-in-class therapeutics that surpass the limitations of current agents.
For further information, visit www.amphista.com.
Contact details: Amphista Therapeutics – John Goodall, Email: [email protected]. ICR Healthcare – Amber Fennell, Namrata Taak, Emily Johnson, Email: [email protected], Phone: +44 (0)20 3709 5813.
